To determine the contribution of the mdr1a gene product to digoxin pharmacokinetics, we
constructed a physiologically based pharmacokinetic model for digoxin in mdr1a (−/−) and …

Background—Although quinidine is known to elevate plasma digoxin concentrations, the
mechanism underlying this interaction is not fully understood. Digoxin is not extensively …

Purpose. To evaluate the MDR1 genotype frequency in the Japanese population and to
study the relationship between the MDR1 genotype and the pharmacokinetics of digoxin …

Background On the basis of in vitro studies indicating that dipyridamole is an inhibitor for the
MDR1 efflux membrane transporter P‐glycoprotein, we postulated that dipyridamole could …

Background The effect of MDR1 C3435T single nucleotide polymorphism (SNP) in exon 26
on digoxin pharmacokinetics has recently been challenged. Objective To clarify the …

Objective: To investigate the effect of single-nucleotide polymorphisms (SNPs) and the
haplotypes of MDR1 on the pharmacokinetics of single-dose digoxin in healthy Chinese …

Objective We investigated the effect of polymorphisms in the P‐glycoprotein (P‐gp) MDR1
gene on steady‐state pharmacokinetics of digoxin in Caucasians. According to earlier data …

Objective Our objective was to quantitate the contribution of the genetic polymorphism of the
human MDR1 gene to the bioavailability and interaction profiles of digoxin, a substrate of P …

We have used mice with a disrupted mdr 1a P-glycoprotein gene (mdr 1a (-/-) mice) to study
the role of P-glycoprotein in the pharmacokinetics of digoxin, a model P-glycoprotein …

The potential multiple carrier-mediated mechanisms involved in the transport of digoxin in
rat intestine were investigated by the rapid filtration method in rat intestinal brush-border …